January 29, 2013 at 13:09 PM EST
Alerts & Trend Analysis Reports on Top Moving Stocks: (NASDAQ: KERX), (NYSE: RSH)
New York, NY -- (SBWIRE) -- 01/29/2013 -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced successful top-line results from the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here